quinazolines has been researched along with Neoplasm Metastasis, Unknown Primary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Ishikawa, D; Mouri, H; Nanjo, S; Ohtsubo, K; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Farley, C; Greco, FA; Hainsworth, JD; Shipley, DL; Spigel, DR; Thompson, DS | 1 |
2 trial(s) available for quinazolines and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Quinazolines; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
3 other study(ies) available for quinazolines and Neoplasm Metastasis, Unknown Primary
| Article | Year |
|---|---|
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasms, Unknown Primary; Quinazolines; Tomography, X-Ray Computed | 2012 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |